|
1
|
El-Shami K, Oeffinger KC, Erb NL, Willis
A, Bretsch JK, Pratt-Chapman ML, Cannady RS, Wong SL, Rose J,
Barbour AL, et al: American cancer society colorectal cancer
survivorship care guidelines. CA Cancer J Clin. 65:428–455. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Keum N and Giovannucci E: Global burden of
colorectal cancer: Emerging trends, risk factors and prevention
strategies. Nat Rev Gastroenterol Hepatol. 16:713–732. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Arnold M, Sierra MS, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global patterns and trends in
colorectal cancer incidence and mortality. Gut. 66:683–691. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ferlay J, Colombet M, Soerjomataram I,
Dyba T, Randi G, Bettio M, Gavin A, Visser O and Bray F: Cancer
incidence and mortality patterns in Europe: Estimates for 40
countries and 25 major cancers in 2018. Eur J Cancer. 103:356–387.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Charrier E, Reibel S, Rogemond V, Aguera
M, Thomasset N and Honnorat J: Collapsin response mediator proteins
(CRMPs): Involvement in nervous system development and adult
neurodegenerative disorders. Mol Neurobiol. 28:51–64. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Quach TT, Honnorat J, Kolattukudy PE,
Khanna R and Duchemin AM: CRMPs: Critical molecules for neurite
morphogenesis and neuropsychiatric diseases. Mol Psychiatry.
20:1037–1045. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tan F, Thiele CJ and Li Z: Collapsin
response mediator proteins: Potential diagnostic and prognostic
biomarkers in cancers (Review). Oncol Lett. 7:1333–1340. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gao X, Mao YH, Xiao C, Li K, Liu W, Li LY
and Pang J: Calpain-2 triggers prostate cancer metastasis via
enhancing CRMP4 promoter methylation through NF-kappaB/DNMT1
signaling pathway. Prostate. 78:682–690. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Moutal A, Honnorat J, Massoma P,
Désormeaux P, Bertrand C, Malleval C, Watrin C, Chounlamountri N,
Mayeur ME, Besançon R, et al: CRMP5 controls glioblastoma cell
proliferation and survival through notch-dependent signaling.
Cancer Res. 75:3519–3528. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gozzard P, Woodhall M, Chapman C, Nibber
A, Waters P, Vincent A, Lang B and Maddison P: Paraneoplastic
neurologic disorders in small cell lung carcinoma: A prospective
study. Neurology. 85:235–239. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Veyrac A, Reibel S, Sacquet J, Mutin M,
Camdessanche JP, Kolattukudy P, Honnorat J and Jourdan F: CRMP5
regulates generation and survival of newborn neurons in olfactory
and hippocampal neurogenic areas of the adult mouse brain. PLoS
One. 6:e237212011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ricard D, Rogemond V, Charrier E, Aguera
M, Bagnard D, Belin MF, Thomasset N and Honnorat J: Isolation and
expression pattern of human Unc-33-like phosphoprotein 6/collapsin
response mediator protein 5 (Ulip6/CRMP5): Coexistence with
Ulip2/CRMP2 in Sema3a- sensitive oligodendrocytes. J Neurosci.
21:7203–7214. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Meyronet D, Massoma P, Thivolet F,
Chalabreysse L, Rogemond V, Schlama A, Honnorat J and Thomasset N:
Extensive expression of collapsin response mediator protein 5
(CRMP5) is a specific marker of high-grade lung neuroendocrine
carcinoma. Am J Surg Pathol. 32:1699–1708. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Morrison DK: MAP kinase pathways. Cold
Spring Harb Perspect Biol. 4:a0112542012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Su B and Karin M: Mitogen-activated
protein kinase cascades and regulation of gene expression. Curr
Opin Immunol. 8:402–411. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Dhillon AS, Hagan S, Rath O and Kolch W:
MAP kinase signalling pathways in cancer. Oncogene. 26:3279–3290.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Burotto M, Chiou VL, Lee JM and Kohn EC:
The MAPK pathway across different malignancies: A new perspective.
Cancer. 120:3446–3456. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lee JS: Exploring cancer genomic data from
the cancer genome atlas project. BMB Rep. 49:607–611. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Seshagiri S, Stawiski EW, Durinck S,
Modrusan Z, Storm EE, Conboy CB, Chaudhuri S, Guan Y, Janakiraman
V, Jaiswal BS, et al: Recurrent R-spondin fusions in colon cancer.
Nature. 488:660–4. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cerami E, Gao J, Dogrusoz U, Gross BE,
Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et
al: The cBio cancer genomics portal: An open platform for exploring
multidimensional cancer genomics data. Cancer Discov. 2:401–404,
2012.22. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Vodenkova S, Buchler T, Cervena K,
Veskrnova V, Vodicka P and Vymetalkova V: 5-fluorouracil and other
fluoropyrimidines in colorectal cancer: Past, present and future.
Pharmacol Ther. 206:1074472019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hammond WA, Swaika A and Mody K:
Pharmacologic resistance in colorectal cancer: A review. Ther Adv
Med Oncol. 8:57–84. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Monstad SE, Nostbakken JK and Vedeler CA:
CRMP5 antibodies found in a patient with limbic encephalitis and
myasthenia gravis. J Neurol Neurosurg Psychiatry. 80:241–242. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Monstad SE, Drivsholm L, Skeie GO, Aarseth
JH and Vedeler CA: CRMP5 antibodies in patients with small-cell
lung cancer or thymoma. Cancer Immunol Immunother. 57:227–232.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang L, Liu W, Tang H, Xie X, Zou C, Wang
Y, Gao Z and Yin J: DRP5 is involved in cancer cell growth and
predicts poor prognosis in human osteosarcoma. Cancer Med.
6:982–993. 2017. View Article : Google Scholar : PubMed/NCBI
|
